NRx Pharmaceuticals Q1 Earnings Call Highlights Progress on Drug Approvals and Financial Improvements
NRx Pharmaceuticals reported progress toward potential FDA approval of KETAFREE, with mostly minor review comments received. The company also plans to file an NDA for NRX-100 in Q2 2026. Additionally, the firm reduced its net loss and improved cash reserves.